Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Eli Lilly is a drug manufacturers-general business based in the US. Eli Lilly stocks (LLY.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $427.24 – an increase of 0.35% over the previous week. Eli Lilly employs 39,000 staff and has a trailing 12-month revenue of around $27.7 billion.
Promoted
National Bank Direct Brokerage
Finder Award
Interactive Brokers
| Latest market close | $427.24 |
|---|---|
| 52-week range | $279.80 - $454.95 |
| 50-day moving average | $387.29 |
| 200-day moving average | $350.87 |
| Wall St. target price | $428.61 |
| PE ratio | 68.0176 |
| Dividend yield | $4.07 (1.06%) |
| Earnings per share (TTM) | $6.26 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $427.24 from 2023-05-30
| 1 week (2023-05-24) | 0.35% |
|---|---|
| 1 month (2023-05-01) | 5.28% |
| 3 months (2023-03-03) | 34.17% |
| 6 months (2022-12-01) | 15.37% |
| 1 year (2022-05-31) | 36.31% |
|---|---|
| 2 years (2021-05-28) | 113.90% |
| 3 years (2020-05-29) | 179.33% |
| 5 years (2018-05-31) | 402.40% |
Valuing Eli Lilly stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Eli Lilly's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
| Revenue TTM | $27.7 billion |
|---|---|
| Operating margin TTM | 27.82% |
| Gross profit TTM | $21.9 billion |
| Return on assets TTM | 9.62% |
| Return on equity TTM | 54.79% |
| Profit margin | 20.54% |
| Book value | $12.44 |
| Market capitalisation | $405.6 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Eli Lilly.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 32.36
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Eli Lilly's overall score of 32.36 (as at 01/01/2019) is pretty weak – landing it in it in the 70th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Eli Lilly is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 0.63/100
Eli Lilly's environmental score of 0.63 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 16.68/100
Eli Lilly's social score of 16.68 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 13.31/100
Eli Lilly's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Eli Lilly is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Eli Lilly scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Eli Lilly hasn't always managed to keep its nose clean.
Dividend payout ratio: 60.81% of net profits
Recently Eli Lilly has paid out, on average, around 60.81% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.06% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Eli Lilly shareholders could enjoy a 1.06% return on their shares, in the form of dividend payments. In Eli Lilly's case, that would currently equate to about $4.07 per share.
Eli Lilly's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Eli Lilly's most recent dividend payout was on 9 June 2023. The latest dividend was paid out to all shareholders who bought their shares by 12 May 2023 (the "ex-dividend date").
Eli Lilly's shares were split on a 2:1 basis on 16 October 1997. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Eli Lilly shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Eli Lilly shares which in turn could have impacted Eli Lilly's share price.
Over the last 12 months, Eli Lilly's shares have ranged in value from as little as $279.8033 up to $454.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Eli Lilly's is 0.367. This would suggest that Eli Lilly's shares are less volatile than average (for this exchange).
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.
Your guide to how ETFs work and whether this type of investment is right for you.
Read more…
The best stock trading app for beginners is easy to use and offers free trades.
Read more…
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.
Read more…Compare some of the best bad credit loans in PEI.
Your guide to the features, interest rates and fees to expect when you apply for a short-term loan with Credito.
Pay for unexpected bills and avoid overdrafts when you sign up for apps like Bree.
Take a closer look at the debt relief solutions, features and fees of Debt Relief Canada.
Learn more about Desjardins Online Brokerage (Disnat) to see if it’s the right broker for you.
We show you the best prepaid credit cards in Canada, whether you’re looking for a prepaid card with no fees, cash back rewards, or travel perks, or more.
This guide provides step-by-step instructions on how to buy Sui, lists some exchanges where you can get it and provides daily price data on (SUI).
Compare apps like Nyble in Canada to access emergency funding.
Your guide to buying and financing a car in Canada with RightRide.
Your guide to bad credit car loans in BC and how to find the right financing for your needs.
